285 related articles for article (PubMed ID: 34290608)
1. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Shen P; Han L; Ba X; Qin K; Tu S
Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
[TBL] [Abstract][Full Text] [Related]
2. Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.
Wei Z; Zhang Y
Cells; 2022 May; 11(11):. PubMed ID: 35681453
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
Liu X; Qiao L
Front Nutr; 2022; 9():810472. PubMed ID: 35399666
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
Toki MI; Syrigos N; Syrigos K
Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
[TBL] [Abstract][Full Text] [Related]
5. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
Wang X; Wang F; Zhong M; Yarden Y; Fu L
Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
[TBL] [Abstract][Full Text] [Related]
9. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.
Zang H; Peng J; Zheng H; Fan S
Front Oncol; 2020; 10():515. PubMed ID: 32411591
[TBL] [Abstract][Full Text] [Related]
11. [Advances in Hyperprogressive Disease in Patients
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
Yao S; Shi K; Zhang Y
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
[TBL] [Abstract][Full Text] [Related]
12. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
[TBL] [Abstract][Full Text] [Related]
14. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhao Z; Bian J; Zhang J; Zhang T; Lu X
Front Oncol; 2022; 12():843707. PubMed ID: 35992878
[TBL] [Abstract][Full Text] [Related]
17. Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
Xiao LS; Li QM; Hu CY; Cui H; Hong C; Huang CY; Li RN; Dong ZY; Zhu HB; Liu L
Ann Palliat Med; 2021 Nov; 10(11):11244-11254. PubMed ID: 34670386
[TBL] [Abstract][Full Text] [Related]
18. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
20. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
Wang Z; Liu C; Bai Y; Zhao X; Cui L; Peng Z; Zhang X; Wang X; Zhao Z; Li J; Shen L
Front Oncol; 2021; 11():761110. PubMed ID: 34858840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
